GoAI
Get started
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc.

AGIO

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$32.905

−$0.25 · -0.76%

Aug 24, 9:44 AM ETData delayed

AGIO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

2

Overpriced

Momentum

64

Gaining

Sentiment

64

Bullish

Risk resilience

58

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Brian Goff
Listed since
Jul 24, 2013
Employees
540

Market position

Volume
24.88K
0.02× average
Average volume
1.16M
Average daily volume
Market cap
1.96B USD
Beta
0.59
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.53B USD
P/E (TTM)
-4.68×
P/B (TTM)
1.9×
P/S (TTM)
19.94×
EV / EBITDA
-3.74×
Earnings yield
-26.16%
Free cash flow yield
-23.91%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
87.92%
Operating margin
-466.78%
Net margin
-418.24%
Return on equity
-34.60%
Return on assets
-31.82%
Return on invested capital
-38.18%

Financial health

Debt / equity
0.03×
Current ratio
11.46×
Altman Z-score
12.96
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2304%473%-1359%-3190%Gross margin, FY2022: 88.03%Gross margin, FY2023: 64.57%Gross margin, FY2024: 88.59%Gross margin, FY2025: 78.67%Operating margin, FY2022: -2732.07%Operating margin, FY2023: -1459.52%Operating margin, FY2024: -1166.47%Operating margin, FY2025: -873.87%Net margin, FY2022: -1627.82%Net margin, FY2023: -1312.63%Net margin, FY2024: 1845.92%Net margin, FY2025: -764.01%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 88.03%. Gross margin FY2023 64.57%. Gross margin FY2024 88.59%. Gross margin FY2025 78.67%. Operating margin FY2022 -2732.07%. Operating margin FY2023 -1459.52%. Operating margin FY2024 -1166.47%. Operating margin FY2025 -873.87%. Net margin FY2022 -1627.82%. Net margin FY2023 -1312.63%. Net margin FY2024 1845.92%. Net margin FY2025 -764.01%.

Income trends

Revenue

54.03M USD+48.03%

Operating income

−472.13M USD-10.90%

Net income

−412.78M USD−1.09B USD
Income trends across reported periods1.81B USD981.66M USD150.92M USD−679.82M USDRevenue, FY2022: 14.24M USDRevenue, FY2023: 26.82M USDRevenue, FY2024: 36.5M USDRevenue, FY2025: 54.03M USDOperating income, FY2021: −378.42M USDOperating income, FY2022: −389.05M USDOperating income, FY2023: −391.49M USDOperating income, FY2024: −425.74M USDOperating income, FY2025: −472.13M USDNet income, FY2021: 1.6B USDNet income, FY2022: −231.8M USDNet income, FY2023: −352.09M USDNet income, FY2024: 673.73M USDNet income, FY2025: −412.78M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 14.24M USD. Revenue FY2023 26.82M USD. Revenue FY2024 36.5M USD. Revenue FY2025 54.03M USD. Operating income FY2021 −378.42M USD. Operating income FY2022 −389.05M USD. Operating income FY2023 −391.49M USD. Operating income FY2024 −425.74M USD. Operating income FY2025 −472.13M USD. Net income FY2021 1.6B USD. Net income FY2022 −231.8M USD. Net income FY2023 −352.09M USD. Net income FY2024 673.73M USD. Net income FY2025 −412.78M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue54.03M USD36.5M USD26.82M USD14.24M USD—
Cost of goods sold11.52M USD4.17M USD9.5M USD1.7M USD18.78M USD
Gross profit42.51M USD32.33M USD17.32M USD12.54M USD−18.78M USD
Research and development334.36M USD301.29M USD288.9M USD279.91M USD256.97M USD
Selling, general, and administrative180.28M USD156.78M USD119.9M USD121.67M USD121.45M USD
Operating expenses514.64M USD458.07M USD408.81M USD401.58M USD359.64M USD
Interest income56.38M USD48.08M USD33.34M USD12.79M USD836K USD
Depreciation and amortization5.18M USD5.65M USD6.62M USD8.56M USD18.78M USD
Operating income−472.13M USD−425.74M USD−391.49M USD−389.05M USD−378.42M USD
Net income−412.78M USD673.73M USD−352.09M USD−231.8M USD1.6B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+2.22%
11 comparable reports
Latest EPS result
-1.69
Estimate -1.65 · Miss by 2.42%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-1.14-1.44-1.74-2.05Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual -1.74, estimate -1.69, surprise -2.96%, Miss. Q2 2025, reported May 1, 2025: actual -1.55, estimate -1.8, surprise +13.89%, Beat. Q3 2025, reported Jul 31, 2025: actual -1.93, estimate -1.74, surprise -10.92%, Miss. Q4 2025, reported Oct 30, 2025: actual -1.78, estimate -1.93, surprise +7.77%, Beat. Q1 2026, reported Feb 12, 2026: actual -1.85, estimate -1.97, surprise +6.09%, Beat. Q2 2026, reported Apr 29, 2026: actual -1.69, estimate -1.81, surprise +6.63%, Beat. Q3 2026, reported Jul 30, 2026: actual -1.69, estimate -1.65, surprise -2.42%, Miss. Q4 2026, reported Oct 29, 2026: actual —, estimate -1.21, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates57.41M40.75M24.08M7.42MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 10.73M USD, estimate 9.35M USD, surprise +14.79%, Beat. Q2 2025, reported May 1, 2025: actual 8.73M USD, estimate 9.99M USD, surprise -12.62%, Miss. Q3 2025, reported Jul 31, 2025: actual 12.46M USD, estimate 10.28M USD, surprise +21.16%, Beat. Q4 2025, reported Oct 30, 2025: actual 12.88M USD, estimate 11.7M USD, surprise +10.09%, Beat. Q1 2026, reported Feb 12, 2026: actual 19.97M USD, estimate 12.09M USD, surprise +65.14%, Beat. Q2 2026, reported Apr 29, 2026: actual 20.75M USD, estimate 13.3M USD, surprise +55.98%, Beat. Q3 2026, reported Jul 30, 2026: actual 44.75M USD, estimate 26.4M USD, surprise +69.52%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 53.8M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$42.67

29.93% upside
Past 12 months12-month forecastHigh $55.00Average $42.67Low $32.00

Rating distribution

29 ratings
Strong buy00%
Buy2276%
Hold724%
Sell00%
Strong sell00%

Recent analyst actions

10 institutions

AGIO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding AGIO

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
70.59M
Weight
0.62%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$162.31-2.06%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
57.01M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.83-0.37%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
49.88M
Weight
0.06%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.48-0.49%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
41.03M
Weight
0.02%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$303.43-0.44%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
23.71M
Weight
0.05%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$354.37-1.19%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
20.56M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.76-0.72%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
17.25M
Weight
0.12%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.96+0.06%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
13.69M
Weight
0.13%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$210.55-1.41%

Continue in GoAI

Research AGIO

research.disclaimer